Article Text

Download PDFPDF
Cystic fibrosis transmembrane conductance regulator modulators for cystic fibrosis: a new dawn?
  1. Claire Edmondson,
  2. Christopher William Course,
  3. Iolo Doull
  1. Respiratory Medicine and Specialised Cystic Fibrosis Unit, Children's Hospital for Wales, Cardiff, UK
  1. Correspondence to Prof Iolo Doull, Department of Paediatric Respiratory Medicine and Specialised Paediatric Cystic Fibrosis Unit, Children's Hospital for Wales, Cardiff CF14 4XN, UK; doullij{at}


Cystic fibrosis (CF) is the most common life-limiting inherited condition in Caucasians. It is a multisystem autosomal recessive disorder caused by variants in the gene for cystic fibrosis transmembrane conductance regulator (CFTR) protein, a cell-surface localised chloride channel that regulates absorption and secretion of salt and water across epithelia. Until recently, the treatment for CF was predicated on ameliorating and preventing the downstream symptoms of CFTR dysfunction, primarily recurrent respiratory infections and pancreatic exocrine failure. But a new class of therapy—the CFTR modulators, which treat the basic defect and decrease the complications of CF, leads to significantly improved pulmonary function, decreased respiratory infections and improved nutrition. The newest agent, a combination of elexacaftor, tezacaftor and ivacaftor, will be suitable for approximately 90% of all people with CF and is likely to decrease the morbidity and significantly increase the life expectancy for most people with CF. The major barrier to their widespread introduction has been their cost, with many countries unwilling or unable to fund them. Nevertheless, such is their therapeutic efficacy and their likely potent effect on life expectancy that their advent has wider societal implications for the care of children and adults with CF.

  • cystic fibrosis
  • pharmacology

Data availability statement

No data are available.

Statistics from

Data availability statement

No data are available.

View Full Text


  • Twitter @chriscourse

  • Correction notice This article has been corrected since it was published online. The first author's surname was spelt incorrectly.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.